20 Dec 2010 07:00
20 December 2010
Plethora Solutions Holdings plc
("Plethora" or "the Company")
Further expansion of product portfolio
Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, is pleased to announce two further product launches before the year end, bringing the number of product launches this year to 11, ahead of the Company's original target.
The new products, Urolieve™ and Virgafem™, have the potential to provide symptomatic relief in patients suffering from chronic bladder pain and stress urinary incontinence respectively and will be made available through Plethora's marketing and distribution subsidiary, The Urology Company Limited.
-Ends-
Enquiries:
Plethora Solutions Steven Powell | Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) Antony Legge (Nomad) / Martin Lampshire (Broker) | Tel : +44(0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce | Tel: +44(0) 20 7947 4350
|
Hansard Communications Kirsty Corcoran | Tel: +44(0) 20 7245 1100
|
Notes to Editors:
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503 - Virgafem), interstitial cystitis (PSD597 - Urolieve) erectile dysfunction (PSD510) and premature ejaculation (PSD502).
Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions.
The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com